OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
13
Results
Show all
Save search
Copy query
Show results for
Unknown
(13)
Release Date
2023
(3)
2025
(2)
2024
(2)
2022
(2)
2021
(2)
2020
(1)
2019
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Rising rural body-mass index is the main driver of the global obesity epidemic in adults.
Not available
S-EPMC6784868
|
biostudies-literature
Cite
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
Not available
S-EPMC7615769
|
biostudies-literature
Cite
Diminishing benefits of urban living for children and adolescents' growth and development.
Not available
S-EPMC10060164
|
biostudies-literature
Cite
Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight.
Not available
S-EPMC7943191
|
biostudies-literature
Cite
Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants.
Not available
S-EPMC7658740
|
biostudies-literature
Cite
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957
|
biostudies-literature
Cite
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774
|
biostudies-literature
Cite
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604
|
biostudies-literature
Cite
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets